In 2015/16, CSL contributed US$29.6 million to patient, biomedical and local communities. Our support for patient communities continues as a priority, with the majority of total funding contributing towards programs that enhance patient quality of life and improve access to our biological medicines. Over the reporting year, CSL partnered with local, national and international patient organisations to raise awareness of serious diseases and improve access. CSL Behring continued its longstanding support of the international haemophilia community, contributing 1.5 million units of coagulation factor to the World Federation of Hemophilia, and in support of a spike of severe influenza cases in Fiji, Seqirus donated 20,000 units of influenza vaccine.

For biomedical communities, CSL invested US$5.1 million in independent investigator-initiated studies to help advance scientific knowledge and improve patient outcomes. Programs, such as the CSL Florey Medal, the CSL Behring Heimburger Awards in Germany, and the inaugural CSL and Walter and Eliza Hall Institute of Medical Research Fellowships in Australia, recognised excellence in biomedical research and helped to encourage the best and brightest to further medical research.

Regionally our sites continue to engage employees in local giving activities, with employee matching programs and community development support making up the bulk of total support.

CSL’S GLOBAL COMMUNITY CONTRIBUTIONS 1 Excludes operations acquired from the Novartis influenza vaccine business.